Investigational drug · Phase 2
HRX215
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Liver Resection, Colorectal Carcinoma Liver Metastases.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "HRX215"
First trial start
2025
May 6, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRX215", any sponsor or status.
Conditions studied
As listed on its trial records.
- Liver Resection
- Colorectal Carcinoma Liver Metastases
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "HRX215" as an intervention, largest first.
HepaRegeniX GmbHIndustry
NCT06638502 · 80 participants (planned) · Start May 6, 2025 · Primary completion Jul 31, 2027
Drug: HRX215 capsules; Placebo capsules · For: Liver Resection; Colorectal Carcinoma Liver Metastases
Sites: Baltimore, Maryland; Rochester, Minnesota; Durham, North Carolina · 14 sites in all
- HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein EmbolizationNot yet recruiting
Mayo ClinicAcademic, hospital or other
NCT07612007 · 80 participants (planned) · Start Dec 1, 2026 · Primary completion Nov 1, 2028
Drug: Darizmetinib; Embolization Therapy and 1 more · For: Metastatic Colorectal Carcinoma; Metastatic Malignant Neoplasm in the Liver; Resectable Colorectal Carcinoma and 1 more
Sites: Rochester, Minnesota
Newest research
PubMed records naming it or its code names, newest first.
- HRX-215 attenuates cartilage fibrosis in osteoarthritis progression and microfracture repair by targeting MKK4.
Zhou Q, Shen Q, Gao Z, et al. · Biochem Pharmacol 2026
- Darizmetinib (HRX215): A Promising 1st-in-Class Liver Regenerating Drug in Phase 1b/2a Clinical Development, Targeting the Stress Signaling Protein Kinase MKK4.
Albrecht W, Selig R, Pfaffenrot B, et al. · J Med Chem 2026
- Targeting the JNK Gatekeepers: Structural Evolution and Medicinal Chemistry of MKK4 and MKK7 Inhibitors.
Zhao M, Li B, Gao Y, et al. · Molecules 2026
- First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure.
Zwirner S, Abu Rmilah AA, Klotz S, et al. · Cell 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.